We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The future of the Centers for Medicare & Medicaid Services’ (CMS) plan to share prescription drug plan data with the FDA in an effort to base Medicare reimbursement on product comparisons is in doubt as the agency determines whether it has the legal authority to share this information, an industry source says.
Leslie Norwalk will serve as acting administrator of the Centers for Medicare & Medicaid Services (CMS) effective Oct. 15, outgoing Administrator Mark McClellan announced in a Sept. 25 email to CMS staff.
HHS’ Office of Inspector General’s (OIG) advisory opinion approving Eli Lilly’s proposed patient assistance program (PAP) should help guide other companies in developing their own programs to supplement the Medicare prescription drug plan, an agency official says.
Leslie Norwalk will serve as acting administrator of the Centers for Medicare & Medicaid Services (CMS) effective Oct. 15, outgoing Administrator Mark McClellan announced in a Sept. 25 email to staff.
Leslie Norwalk will serve as acting administrator of the Centers for Medicare & Medicaid Services (CMS) effective Oct. 15, outgoing Administrator Mark McClellan announced in a Sept. 25 email to staff.
HHS’ Office of Inspector General’s (OIG) advisory opinion approving Eli Lilly’s proposed patient assistance program (PAP) should help other companies develop their own programs to supplement the Medicare prescription drug plan, an agency official says.
A new study appears to support the device industry’s contention that advanced technology is worth its high cost and that reimbursement policies should reflect that value.
Flaws in the Centers for Medicare & Medicaid Services’ (CMS) reimbursement policy for Amgen’s anemia drug Epogen may foretell problems with the Part D drug plan, researchers say.
The Centers for Medicare & Medicaid Services (CMS) reimbursement policy for Amgen’s anemia drug Epogen is based on flawed and incomplete data, contradicting the FDA and foretelling potential problems with the Part D drug plan, researchers say.
Centers for Medicare & Medicaid Services head Mark McClellan became the latest Bush staffer to leave when he announced Sept. 5 that he will resign in early October, saying it was a “good time for a transition,” with the agency’s programs in a “fundamentally good position.”